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STUDY PROTOCOL Open Access
Can exercise ameliorate treatment toxicity during
the initial phase of testosterone deprivation in
prostate cancer patients? Is this more effective
than delayed rehabilitation?
Robert U Newton1*, Dennis R Taaffe1,2,3, Nigel Spry1,4,5, Prue Cormie1, Suzanne K Chambers1,6, Robert A Gardiner1,7,
David HK Shum6, David Joseph1,4,5 and Daniel A Galvão1
Abstract
Background: There has been substantial increase in use of androgen deprivation therapy as adjuvant management
of prostate cancer. However, this leads to a range of musculoskeletal toxicities including reduced bone mass and
increased skeletal fractures compounded with rapid metabolic alterations, including increased body fat, reduced
lean mass, insulin resistance and negative lipoprotein profile, increased incidence of cardiovascular and metabolic
morbidity, greater distress and reduced quality of life. Numerous research studies have demonstrated certain
exercise prescriptions to be effective at preventing or even reversing these treatment toxicities. However, all
interventions to date have been of rehabilitative intent being implemented after a minimum of 3 months since
initiation of androgen deprivation, by which time considerable physical and psychological health problems have
manifested. The pressing question is whether it is more efficacious to commence exercise therapy at the same time
as initiating androgen deprivation, so treatment induced adverse effects can be immediately attenuated or indeed
prevented.
Methods/design: We are proposing a multi-site randomized controlled trial with partial crossover to examine the
effects of timing of exercise implementation (immediate or delayed) on preserving long-term skeletal health,
reversing short- and long-term metabolic and cardiovascular risk factors, and supporting mental health in men
receiving androgen deprivation therapy. 124 men who are about to initiate androgen deprivation for prostate
cancer will be randomized to immediate or delayed groups. Immediate will commence a 6-month exercise
program within 7–10 days of their first dose. Delayed will receive usual care for 6 months and then commence the
exercise program for 6 months (partial cross-over). Immediate will be free to adopt the lifestyle of their choosing
following the initial 6-month intervention. Measurements for primary and secondary endpoints will take place at
baseline, 6 months and 12 months.
Discussion: This project is unique as it explores a fundamental question of when exercise implementation will be
of most benefit and addresses both physical and psychological consequences of androgen deprivation initiation.
The final outcome may be adjunct treatment which will reduce if not prevent the toxicities of androgen
deprivation, ultimately resulting in reduced morbidity and mortality for men with prostate cancer.
Trial registration: ACTRN12612000097842
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Background
There has been a substantial increase in the use of tem-
porary androgen deprivation therapy (ADT) as an adju-
vant to radical radiation and surgical therapies for
management of prostate cancer[1,2] with substantial
periods of ADT now routinely applied to improve out-
comes at 5, 10 and 15 years post diagnosis[2-4]. More
than 2,000 men in Australia[5] and more than 80,000 in
the USA[6] commence on-going ADT for prostate can-
cer each year. However, ADT leads to a range of well-
established musculoskeletal toxicities including reduced
bone mass and increased skeletal fractures[7,8] com-
pounded with rapid metabolic alterations including
increased body fat, loss of lean mass, insulin resistance
and negative lipoprotein profile[9-15]. Recent work, in-
cluding our own current Australian cohort, suggests an
increased incidence of cardiovascular and metabolic
morbidity associated with temporary ADT[16-20] and
we have also reported significantly increased distress[21]
and reduced quality of life (QOL)[22,23]. Our team has
shown that even a 9-month exposure to ADT leads to
significant reductions in bone mass across different clin-
ical sites concurrent with severe loss of lean mass and
increased trunk and whole body fat mass, all surrogate
indicators of osteoporosis/skeletal fractures and cardio-
vascular/metabolic complications[15]. Currently, there is
no established treatment to reverse bone loss and the
array of metabolic adverse effects associated with severe
hypogonadism from temporary ADT. Preliminary clin-
ical trials by our team[24-26] and others[27,28] have
suggested high efficacy of exercise for these patients but
evidence is limited to only a few studies with men on
long-term androgen deprivation[24,27-29]. We have
shown that a combined program of resistance and aer-
obic exercise leads to a number of significant and clinic-
ally meaningful benefits including reversal of muscle loss
in men receiving ADT for an average of approximately
14 months[24]. A critical but as yet unanswered research
question is to determine whether it is more efficacious
to commence exercise therapy at the onset of androgen
deprivation so treatment induced adverse effects can im-
mediately be attenuated or even completely prevented.
This has not been addressed in any exercise trials to date
and has the potential to prevent much of the ADT toxi-
cities from the outset rather than try to rehabilitate the
patient from the effects of long-term ADT later. A re-
cent report[30] showed that physical function and quality
of life are compromised within 3 months of commencing
ADT suggesting that up-front exercise interventions are
needed to counteract these losses, as well as the marked
reductions in bone density and bone strength. Import-
antly, it appears the initial beneficial effects of resistance
and aerobic exercise programs are similar for neuromus-
cular and physical function regardless of whether patients
are on acute (3–6 months) or chronic (>6 months) ADT
[31]. Such preliminary evidence supports the hypothesis
that exercise might be best initiated when ADT com-
mences, to enhance physical function, retain structure and
improve the patient’s acceptance of hormone therapy. This
is an important finding as it suggests that exercise may
still benefit men during acute ADT, but no research has
trialled this from time zero; that is initiation of ADT. This
is a considerable gap in our understanding of the manage-
ment of prostate cancer and ADT.
Having successfully completed several pilot studies, a
randomised controlled trial (RCT) and ongoing RCTs in
prostate cancer[24-26,31-34], this trial will drill down to
the specifics of exercise as medicine to improve skeletal
health, physical function, quality of life and mental
health implemented immediately when patients initiate
ADT. We propose a RCT with partial crossover to
examine the effects of the timing of exercise implemen-
tation. We will evaluate the following hypotheses:
1) It is more efficacious to commence exercise therapy at
the onset rather than after six months of ADT; and
2) ADT side effects, in particular the substantial initial
bone loss, can be prevented by a 6-month exercise
program concurrently undertaken at the onset of ADT.
The primary endpoint will be spine and hip aBMD
determined by DXA. Secondary endpoints will include:
1) volumetric BMD (vBMD) and micro-architecture
at the tibia, 2) body composition (lean mass and fat
mass/abdominal obesity), 3) blood pathology (glucose
metabolism, lipid profile, prostate specific antigen
(PSA), testosterone, bone formation and resorption mar-
kers), 4) physical function, muscle strength and balance, 5)
physical activity level and motivation, and 6) health-
related quality of life and psychological distress.
The ultimate outcome will be guidelines for the pre-
scription of exercise for the prevention of ADT toxici-
ties, primarily those related to long-term skeletal health
and physical function. This project is unique as it
explores a fundamental question of when exercise imple-
mentation will be of most benefit to men undertaking
ADT. The final outcome may be an adjunct treatment
which will prevent major toxicities of ADT, ultimately
resulting in reduced morbidity and mortality for men
with prostate cancer.
Methods/design
We are proposing a single-blinded (investigators and test-
ing personnel blinded to group allocation) RCT with partial
crossover to examine the effects of the timing of exercise
implementation. An immediate exercise group (IE) will
undertake the exercise program for 6 months. After
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6 months, the delayed exercise group (DE) will be crossed
to receive the same intervention program (Table 1).
Recruitment
Subjects will be recruited by invitation of their spe-
cialist (radiation oncologist/urologist) as previously
reported in completed and ongoing trials [24,26,32].
Those entering the study will undertake a series of
familiarisation sessions and baseline measurements
prior to randomisation (Figure 1).
Randomisation and stratification
Patients will be randomly allocated in a ratio of 1:1 to
the two treatment arms for IE and DE groups, subject to
maintaining approximate balance regarding stratification
for age (<=70 yr>) and smoking status (yes/no). A
research methods consultant will be responsible for this
randomisation and confirming the groups are balanced
on these parameters. The chief investigators, exercise
physiologists, psychologists and other researchers con-
ducting the study measures will be blinded to a given
participant’s group allocation. The exercise intervention
will be provided by exercise physiologists not in the
research team or performing the tests (single blinded).
Subjects
One hundred and twenty-four men (62 subjects per
arm) beginning treatment for prostate cancer involving
ADT with no regular exercise (undertaking structured
aerobic or resistance training two or more times per
week) within the past 3 months will be recruited by invi-
tation of their attending specialist in the Perth, Western
Australia, and the Central Coast region of New South
Wales. All participants will be able to walk 400-m and
will require physician consent. Exclusion criteria will in-
clude prior exposure to ADT (e.g. those re-initiating
ADT from intermittent programs), existing hypogonad-
ism, established metastatic bone disease, established
osteoporosis, those taking medications known to affect
bone metabolism (e.g. bisphosphonates), acute illness or
any musculoskeletal, cardiovascular or neurological dis-
order that could inhibit or put them at risk from exercising.
The protocol has been approved (ID: 7869 NEWTON) by
the University Human Research Ethics Committee and all
subjects will provide written informed consent.
Measurements
All measurements for primary and secondary endpoints
will take place at baseline, 6 and 12 months. Additional
blood measures, scans and questionnaires will also be
undertaken at 3 months to track changes over time dur-
ing the initial 6 months for bone formation and resorp-
tion markers. Body composition measures for muscle
and fat mass will also be performed at 3-month intervals
to track the trajectory of change in these outcomes.
Calcium and vitamin D
All participants will receive standard daily supplementation
with calcium (1,000 mg/d) and vitamin D3 (800 IU/d).
Primary study endpoints
Areal BMD
BMD (g/cm2) of the hip (total hip) and lumbar spine
(L2-4) as well as whole body bone mineral content
(BMC, g) will be assessed by DXA (Hologic Discovery A,
Waltham, MA). The Instant Vertebral Assessment (IVA)
and Quantitative Morphometry (QM) program will be
used to determine the presence or absence of vertebral
fractures prior to initiation of the study.
Secondary study endpoints
Volumetric BMD and bone architecture
Three dimensional pQCT (XCT3000, Stratec, Pforzheim,
Germany) will be used to measure volumetric BMD and
micro-architecture at the tibia. This technique provides
additional data on trabecular and cortical density and
geometry with actual prediction of fracture thresholds.
Methods for analysis will be as previously described[35].
Body composition
In addition to BMD, regional and whole body lean mass
(including appendicular skeletal muscle mass) and fat
mass will be derived from the whole body DXA scan.
Measurement of trunk adiposity is an important indicator
of chronic disease risk, and will be assessed from trunk fat
mass obtained from the whole body scan and the ratios of
trunk fat to limb fat, and trunk fat to total fat. Images from
the pQCT scans will also be analysed for muscle density
and cross-sectional area for the lower limbs.
Blood markers
Testosterone, prostate specific antigen (PSA), insulin,
glucose, haemoglobin A1c (HbA1c), C-reactive protein
(CRP), bone formation [alkaline phosphatase, Pro col-
lagen Type 1 N-Terminal Pro peptide (PINP)] and re-
sorption [C-terminal telopeptide of type I collagen
(CTX)] markers, vitamin D and lipid profile levels will
be measured commercially by an accredited Australian
National Association of Testing Authorities (NATA)




Exercise Intervention No formal intervention
Delayed Exercise
(n=62)
Usual Care Exercise Intervention
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laboratory (Pathwest Diagnostics, Perth, Western
Australia)[24].
Blood pressure and arterial stiffness
A validated oscillometric device (HEM-705CP, Omron Cor-
poration, Japan) will be used to record brachial BP at the
dominant arm in triplicate. Central (ascending aortic) BP
and indices of arterial stiffness will be determined using a
SphygmoCor system (AtCor Medical, Sydney, Australia).
Radial artery pressure waveforms will be captured at the
right arm by applanation tonometry using a high fidelity
micromanometer (SPC-301, Millar Instruments, Houston,
Texas, USA). A generalised transfer function is applied to
the radial artery waveform in order to obtain the pressure
waveform at the ascending aorta. This method has been
validated against invasive techniques for determination of
central BP and the augmentation index (AIx) is a marker of
systemic arterial stiffness.
Muscle strength and balance
Prior to muscle testing, subjects will be familiarised with
all assessment procedures. In addition, a warm-up
consisting of aerobic activity and stretching will be
undertaken. Dynamic concentric muscle strength for the
leg press, chest press and seated row undertaken in the
program will be measured using the one repetition max-
imum (1-RM) method. The 1-RM is the maximal weight
an individual can move through a full range of motion
without change in body position other than that dictated
by the specific exercise motion[36]. A Neurocom Smart
Balancemaster (Neurocom, OR, USA) will be used to as-
sess standing balance. This device measures ground re-
action force to track whole body centre of pressure and
a tilting visual field and support platform to separate the
visual, somatosensory and vestibular balance sense of
the patient. Falls self-efficacy will be determined using
the Activities-Specific Balance Confidence scale. Du-
ring the course of the intervention, all participants will
record any falls that take place and submit monthly
fall records to the investigators.
Objective measures of physical function
A battery of tests will be used to assess functional per-
formance[24,37]. Tests will be performed in triplicate
Referral by Oncologists/Urologists
Western Australia/NSW






Patients stratified and randomly 
assigned (n = 124)
Asked to maintain usual 
physical activity for 6 months
12 month testing12 month testing
6 month testing 6 month testing
Receive allocated 
intervention for 6 months
Asked to maintain usual physical 
activity for 6 months
Receive allocated 
intervention for 6 months
Figure 1 CONSORT Diagram.
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(except for the 400-m walk which will be performed
once) with sufficient recovery time between trials. The
best performance on each test will be used in the
analyses. The tests will be; 1) repeated chair rise, 2) stair
climb, 3) 6-m backward tandem walk, 4) 6-m walk,
usual and fast pace, and 5) 400-m walk. Performance in
each test will be timed electronically using a Kinematic
Measurement System (Fitness Technology, Australia)
Physical activity level and motivation
Self-reported physical activity will be assessed by the leis-
ure score index from the Godin Leisure-Time Exercise
Questionnaire. ActiGraph activity monitors (triaxial accel-
erometer, GT3X+, Actigraph, Pensacola, Florida) will be
used to objectively assess physical activity levels and
sedentary time over a 7-day period[38]. A 6-item ques-
tionnaire will be used to assess the domain-specific
sedentary behaviour.
The Theory of Planned Behaviour (TPB) is the most
widely utilised behavioural framework when examining
physical activity motivation in cancer survivors. There-
fore, physical activity motivation will be assessed in ac-
cordance with the TPB. TPB constructs (affective and
instrumental attitude, injunctive and descriptive norm,
self-efficacy, perceived behavioural control, intention,
and planning) will be assessed in accordance with estab-
lished guidelines using standardised items[39].
Health-related quality of life and psychological distress
Health-related QOL will be measured using the Medical
Outcomes Study Short-Form 36 (SF-36), European
Organisation for Research and Treatment of Cancer
(EORTC) QLQ-C30 and EORTC QLQ-PR25 as well as a
health history questionnaire. This validated instrument
is an integrated system to assess QOL in cancer patients
and has been extensively employed in clinical trials[40].
The Brief Symptom Inventory-18 (BSI-18) will be used
to assess psychological distress (Anxiety, Depression and
Somatisation)[21]. Higher somatization and anxiety as
measured by the BSI-18 is associated with greater phys-
ical inactivity in cancer survivors[21]. The Impact of
Events Scale (IES) and the Memorial Anxiety Scale for
Prostate Cancer (MAX-PC) will be used to measure can-
cer specific distress[41,42]. A core self-evaluation ques-
tionnaire and lifestyle individual resilience scale will be
used to assess core self-evaluation and three related
aspects of resilience (individual, social–peers and social–
family resources). Fatigue will be assessed using the
Functional Assessment of Chronic Illness Therapy-
Fatigue (FACIT-F) questionnaire. The FACIT-F is a 13
item scale commonly used to assess fatigue in cancer
patients[43] as well as cancer patients receiving exercise
interventions[44]. Items from the Pittsburgh Sleep Qual-
ity Index (PSQI) will be used to measure sleep quality
[45]. The PSQI is used to assess quality of sleep over a
1-month interval, and has been shown to be reliable and
sensitive to change[46].
Exercise intervention
The intervention program will comprise resistance, aer-
obic and impact-loading exercises undertaken 3 times
per week in an exercise clinic. The frequency of resist-
ance and aerobic exercises will alternate weekly so two
aerobic/impact loading and one resistance/impact load-
ing sessions are performed in the first week and two re-
sistance/impact loading and one aerobic/impact loading
are performed in the subsequent week. Resistance train-
ing sessions will take approximately 60 minutes (this
includes the warm-up and cool-down periods) and will
be conducted in the Exercise Clinics at Edith Cowan
University (ECU) in Perth and seven other partner sites
in Western Australia: Perth; Mandurah; and Bunbury.
We also have another site at the University of Newcastle
where we have identical equipment and procedures. The
programme will include exercises such as leg press, leg
extension, leg curl, chest press, seated row, lat pulldown
and bicep curl that target the major upper and lower
body muscle groups, which we have used in a number of
previous studies[24,26,37,47] including men on ADT. To
ensure the progressive nature of the training program,
subjects will be encouraged to work past the specific
repetition maximums (RMs) prescribed. The resistance
will be increased by 5-10% increment for the next set/
training session if the subject is able to perform more
repetitions than the RMs specified during a set. Intensity
will be manipulated from 6-12-RM (e.g. the maximal
weight that can be lifted 6 to 12 times) using 1–4 sets
per exercise. The aerobic component will include 25–
40 minutes of cardiovascular exercise using various
modes such as walking or jogging on a treadmill, cycling
or rowing a stationary ergometer, or exercising on a
cross training machine. Target intensity will be 60-85%
estimated maximum heart (220–age) with individual
heart rate watches (Polar Electra Oy, Finland) provided
for each participant. In addition to the clinic training,
participants will be encouraged to undertake twice
weekly home-based training incorporating aerobic activ-
ity (e.g. walking, cycling) and a modified version of the
impact-loading regimen (only including hopping, leaping
and drop jumping) for the duration of the study. The
impact-loading regimen will be performed a minimum
of 3 times per week for the duration of the trial, in com-
bination with the resistance and aerobic exercise. For
the first 10 weeks, 2 rotations will be performed of skip-
ping (30 sec), bounding over soft hurdles (13–16 cm), and
drop jumping (10–15 cm). In the second 10-week period,
hopping on one leg (10 times) will be added, leaping (10
times) will replace skipping, and 4 rotations of bounding
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(19–25 cm), drop jumping (20–25 cm), hopping, and leap-
ing will be performed for the remainder of the
programme. These activities result in substantial peak
ground reaction forces ranging from 3.4 to 5.2 times body
weight providing excellent stimulus to bone yet proven
safe and accepted by older people[48].
All exercise sessions will be conducted in small groups
of up to 6–10, with participants exercising in pairs and
under direct supervision to ensure correct technique
and minimize the risk for injury. Each session will com-
mence with a 10-minute warm-up comprising low-level
aerobic activities such as walking and stationary cycling,
as well as stretching and conclude with a 5-minute cool-
down period of stretching activities. In order to reduce
the possibility of boredom and overreaching the exercise
program will be periodised by cycling emphasis on in-
tensity and volume. Also, within sessions variations of
circuit training and intermittent exercise sessions (inter-
vals of high and low intensity exercise) will be intro-
duced. The exercise program will be designed to provide
optimal stimulus to the skeletal, cardiorespiratory and
neuromuscular systems while maximizing compliance
and retention. All participants will be asked to maintain
customary physical activity and dietary patterns over the
intervention period (apart from the programmed exer-
cise). Physical activity and dietary intake will be assessed
at baseline, 6 and 12 months. During the course of the
study, participants will be required to maintain an
activity log and record their recreational physical ac-
tivities. Participants in the DE group will be con-
tacted every 4 weeks to encourage them to maintain
current physical activity levels and record their activ-
ities. Dietary intake, at the same time points as for
physical activity, will be assessed using a 4-day diet-
ary record. Dietary information will be derived using
the FoodWorks software program.
Calculation of sample size
Data from our 36-week study[15] in prostate cancer sur-
vivors initiating ADT indicates that the standard devi-
ation (SD) for change in our primary outcome of BMD
equates to approximately 4.5% and 3.3%, for the hip and
lumbar spine, respectively. With ADT, the annual loss is
reported to be 2-8% at the spine and 1.8-6.5% at the hip
[49,50] and based on our 36-week data, we obtained an
initial loss of 1.5% and 3.9% for the hip and lumbar
spine, respectively. Therefore, we anticipate losses of ap-
proximately 1.5% and 3.5% at the clinically relevant frac-
ture sites of the hip and spine. We anticipate a
difference between the immediate and delayed exercise
groups of approximately 2.5% at the hip and 4.5% at the
lumbar spine, which would be clinically significant and
substantially reduce the risk for fracture. A priori, 51
subjects per group will be required to achieve 80%
power at an alpha level of 0.05 (two-tailed), and to dem-
onstrate a difference between groups at each bone site at
the end of the 6-month intervention. Previous experi-
ence in our exercise trials indicates an attrition rate of
up to 20% over the course of the study period. There-
fore, to adequately ensure that we have sufficient subject
numbers at the end of the intervention, 124 subjects will
be randomised in a ratio of 1:1 to the immediate and
delayed exercise groups, respectively. A sample size of
124 will also provide us with sufficient power to detect
differences in our secondary outcomes which all have
larger effect sizes based on our previous research.
Statistical analysis
Data will be analysed using SPSS statistical software
package and an intention-to-treat approach will be
applied. Analyses will include standard descriptive statis-
tics, Student’s t tests, correlation and regression, and
two-way (group x time) repeated measures ANOVA (or
ANCOVA as appropriate) to examine differences be-
tween groups over time. All tests will be two-tailed and
an alpha level of 0.05 will be applied as the criterion for
statistical significance.
Discussion
This is the first intervention using a combination of re-
sistance, aerobic and impact loading exercise implemen-
ted immediately with initiation of ADT as opposed to
long-term androgen deprivation. The principal outcome
of this project will be the determination of whether it is
more efficacious to commence exercise therapy at the onset
of ADT so treatment induced adverse effects can be imme-
diately attenuated or even completely prevented. This is an
exciting possibility. Second, this is the first study to our
knowledge using pQCT to assess bone outcomes of a
therapeutic exercise intervention in a cancer population.
Importantly, this simple and cost effective intervention
strategy may provide comparable benefits to pharmaceut-
ical interventions (e.g. bisphosphonates) without exposing
patients to additional potential side effects[36,51,52] or the
high financial cost of these drugs. The most important out-
come will be clinical guidelines for the concurrent prescrip-
tion of exercise for the management of men initiating ADT
to preserve long-term skeletal health, reduce metabolic and
cardiovascular morbidities, maintain physical function and
alleviate psychological distress and depression associated
with severe hypogonadism resulting from temporary ADT.
By examining psychological outcomes of depression and
distress we are addressing all aspects of ADT toxicities in
the initiation phase, an important time when patient dis-
comfort is greatest but unfortunately not addressed to date.
This holistic approach to ADT toxicity will result in more
effective clinical guidelines for managing patients, in par-
ticular maximizing uptake and long term adherence of
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exercise therapy. In terms of advancement of prostate can-
cer care, we expect dissemination of the knowledge gained
from this project to reduce fracture risk, improve physical
and functional ability, quality of life, mental health and ul-
timately survival rates in this population. In particular, we
hope to establish that exercise implemented as men initiate
ADT can offer an array of positive patient outcomes and
this strategy is far superior to the current delayed rehabilita-
tion approach. Such benefits, apart from enhancing quality
of life, could significantly reduce health care costs and ul-
timately increase survivorship.
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